Aegis Sciences Corporation, a leading national healthcare and forensic toxicology laboratory, has announced the successful completion of a $170 million debt refinancing, advised by CoveView Advisors. Aegis is a portfolio company of Abry Partners, a leading sector-focused North American private equity firm. In addition to contributions from new debt investors led by Kayne Anderson, Abry Partners is providing incremental growth equity capital to support Aegis’s ambitious expansion plans. As part of the transaction, Aegis also retains an undrawn revolving credit facility which will be used to finance future growth investments.

“We appreciate the tremendous support from both existing and new investors as we successfully close this important financing for the company,” said Dr. Frank Basile, Chief Executive Officer of Aegis. “Aegis’s track record of product leadership, strong organic growth, and accelerating operational efficiency places us in a strong position to fully leverage our best-in-class platform in what remains a highly fragmented sector.”

Read full press release here.